Medical Condition News

RSS

National Standards Report on ASD treatments released by National Autism Center

The National Autism Center, a nonprofit organization dedicated to serving individuals with Autism Spectrum Disorders (ASD), today released its National Standards Report, the most comprehensive analysis of treatments for children and adolescents with ASD ever published.

22 Sep 2009

NicOx announces publication of blood pressure results from the phase 3 study of naproxcinod

NicOx S.A. (NYSE Euronext Paris: COX) today announced that an important scientific article has been published in the September issue of the American Journal of Cardiology. The publication describes the blood pressure results from the 301 phase 3 study for naproxcinod in detail. Naproxcinod is the first-in-class Cyclooxygenase-Inhibiting Nitric Oxide Donating (CINOD) anti-inflammatory agent for the relief of the signs and symptoms of osteoarthritis (OA).

22 Sep 2009

UAB's researchers find early indicators for Alzheimer's disease

Inability to handle financial transactions or manage money may be an early indicator that a person with mild memory problems soon is likely to develop Alzheimer's disease, according to new research from the University of Alabama at Birmingham (UAB) Alzheimer's Disease Center, part of the Department of Neurology.

22 Sep 2009

Veterans Healing Initiative formed for veterans suffering from PTSD

The Veterans Healing Initiative (VHI) has been formed in response to the dramatic increase of Substance Abuse (SA) and co-occurring mental health disorders among U.S. Veterans. Formed by Margaret Stone and James L. Abernathy, VHI's core mission is to raise funds for veterans who need treatment for Addiction and Post Traumatic Stress Disorder (PTSD) and help them begin to heal the war within.

22 Sep 2009

Late diagnosis of bipolar disorder in children and adults

75% of the cases of paediatric bipolar disorder are diagnosed late - up to 18 months - due to the symptoms manifesting themselves in a different manner depending on whether the patient is a child or adult. Moreover, 25% of sufferers have a delay in their medical diagnoses of up to three years and four months, according to a study by the Department of Psychiatry and Medical Psychology at the University Hospital of Navarra, in collaboration with the Paediatric Psychopharmacology Unit at the l Massachusetts General Hospital at Harvard University (Boston, United States).

22 Sep 2009

Amorfix announces 100% specificity upon testing 10,000 blood donations for vCJD

Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases, today announced it has achieved 100% specificity (no reproducible false positive results) upon testing 10,000 blood donations for variant Creutzfeldt-Jakob Disease ("vCJD"). with the EP-vCJD(TM) Blood Screening Assay at l'Etablissement Français du Sang de Pyrénées Méditerrannée ("EFS-PM") in Montpellier, France.

22 Sep 2009

Researchers to present results of HORIZONS-AMI trial at TCT scientific symposium

Two subset analyses from the landmark HORIZONS-AMI trial show that the anticoagulant bivalirudin lowers major bleeding and cardiac death versus the combination of heparin and a GP IIb/IIIa inhibitor in patients with ST-segment myocardial infarction (STEMI) who have disease of the left anterior descending artery (LAD), while in STEMI patients at highest risk for death, bivalirudin also confers the greatest mortality benefit.

22 Sep 2009

Three-year clinical results of Medtronic's Resolute Zotarolimus-Eluting Coronary Stent released

New clinical data released today at a major meeting of interventional cardiologists show strong and sustained efficacy and safety of the Resolute® Zotarolimus-Eluting Coronary Stent from Medtronic, Inc. (NYSE: MDT) in long-term patient follow-up.

22 Sep 2009

Bioscience Research offers mental health care at no cost

Psychiatrists at Bioscience Research, LLC, understand the mental health burden that can accompany unemployment and the day-to-day stress of looking for a new job or worrying about losing an existing job.

22 Sep 2009

New sirolimus-eluting stent shows greater neointimal suppression than PES

A new type of sirolimus-eluting stent (SES) successfully showed significantly greater neointimal suppression than the paclitaxel-eluting stent (PES) with greater vessel wall integrity surrounding the stent, confirming the finding of superiority of the SES over the PES stent for the trial's primary endpoint of in-stent late loss.

22 Sep 2009

IRSF announces funding of new clinical study with disease-modifying therapy treatment for Rett syndrome

Today, the International Rett Syndrome Foundation announced that it will provide $200,000 in 2009 to support a newly proposed clinical trial with a growth-factor based treatment for Rett Syndrome. The study will be carried out by a team of clinical trials specialists at the Boston Children's Hospital, led by Dr. Omar Khwaja MD, PhD and will be the first potentially disease modifying therapy ever to be tested in Rett syndrome patients.

22 Sep 2009

Major shift in cancer research priorities needed

Cancer research is too focused on new drug development, while not enough money and effort is being devoted to pursuing important advances in knowledge likely to have the biggest impact on combating the disease in the next few decades, a leading research policy expert says, adding that a major shift in research priorities will be crucial to the ability to cope with the coming wave of cancer cases.

22 Sep 2009

Drug-eluting stents effective for diabetic patients

Results of a multicenter study in Asia, demonstrating that drug-eluting stents are effective with a low rate of complications in diabetic patients, will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

22 Sep 2009

Diabetes more prevalent in African Americans due to living conditions

The higher incidence of diabetes among African Americans when compared to whites may have more to do with living conditions than genetics, according to a study led by researchers at the Johns Hopkins Bloomberg School of Public Health. The study, available online in advance of publication in the October 2009 edition of the Journal of General Internal Medicine, found that when African Americans and whites live in similar environments and have similar incomes, their diabetes rates are similar, which contrasts with the fact that nationally diabetes is more prevalent among African Americans than whites.

22 Sep 2009

Survey: 77% of Latino women avoid milk to manage lactose intolerance

A new Lactose Intolerance in Multicultural Communities Survey sponsored by the LACTAID(R) Brand found that 77 percent of Latinas reduce the amount of milk or dairy in their diet as a way to manage their lactose intolerance. Yet, 63 percent of Latinas who have lactose intolerance worry the condition keeps them from consuming important nutrients, such as calcium and vitamins A and D. Despite their concerns, only 14 percent have talked to a health care professional about lactose intolerance.

22 Sep 2009

35 million people around the world affected by Alzheimer's disease: Nancy Pelosi

"Alzheimer's disease is a scourge afflicting Americans in every state and community. According to a new report, it affects 35 million people around the world -- and that number is expected to nearly double in 20 years, to more than 65 million in 2030.

22 Sep 2009

Poor money management: A sign of developing Alzheimer's disease

New research finds poor money management skills may indicate that a person with mild memory problems will soon develop Alzheimer's disease. The study is published in the September 22, 2009, print issue of Neurology, the medical journal of the American Academy of Neurology.

22 Sep 2009

Amgen announces Phase 3 results evaluating Vectibix in combination with FOLFIRI chemotherapy

Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.

22 Sep 2009

Moses Cone Health System installs TomoTherapy cancer treatment system

TomoTherapy Incorporated announced today that Moses Cone Health System has installed North Carolina's first TomoTherapy® cancer treatment system at the Moses Cone Regional Cancer Center in Greensboro, N.C.

22 Sep 2009

Survey: 78% of African American women avoid milk to manage lactose intolerance

A new Lactose Intolerance in Multicultural Communities Survey sponsored by the LACTAID(R) Brand found that 78 percent of African American women reduce the amount of milk or dairy in their diet as a way to manage their lactose intolerance. Yet, 48 percent of African American women who have lactose intolerance worry the condition keeps them from consuming important nutrients, such as calcium and vitamins A and D. Despite their concerns, only 16 percent have talked to a health care professional about lactose intolerance.

22 Sep 2009